Lite Strategy

Lite Strategy R&D per Employee

The R&D Spending per Employee of Lite Strategy (LITS) as of Nov 20, 2026 is 30,500.00 USD. In the previous year, R&D Spending per Employee was 980,750.00 USD — a change of -96.89% (lower).

R&D per Employee

30,500.00USD

YoY

-96.89%

Last updated:

R&D Spending per Employee of Lite Strategy is 2026 30,500.00 USD. R&D Spending per Employee of Lite Strategy was 2025 980,750.00 USD. It decreases by -96.89% lower compared to the previous year.

The Lite Strategy R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2019
8.08 M USD
Jan 1, 2020
8.52 M USD
Jan 1, 2021
17.35 M USD
Jan 1, 2022
21.41 M USD
Jan 1, 2023
13.11 M USD
Jan 1, 2024
4.14 M USD
Jan 1, 2025
980,750.00 USD
Jan 1, 2026
30,500.00 USD
The Lite Strategy R&D per Employee history
YEARR&D per EmployeeYoY
30,500.00USD-96.89%
980,750.00USD-76.31%
4.14 MUSD-68.43%
13.11 MUSD-38.76%
21.41 MUSD+23.41%
17.35 MUSD+103.69%
8.52 MUSD+5.48%
8.08 MUSD+89.55%
4.26 MUSD+135.36%
1.81 MUSD-45.97%
3.35 MUSD-43.74%
5.96 MUSD+23.23%
4.83 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lite Strategy Stock analysis

What does Lite Strategy do? MEI Pharma, Inc. develops cancer therapies, focusing on clinical drug candidates including Pracinostat, ME-344, and ME-401. Pracinostat, an HDAC inhibitor for hematologic diseases like AML and MDS, has undergone Phase I and II trials. ME-344 targets mitochondrial components in rapidly proliferating cells, while ME-401 inhibits PI3K delta for hematologic cancer treatment. The company generates revenue through clinical development and potential future drug sales, targeting oncology markets with its pipeline of cancer therapies. The firm's products are developed for specific cancer indications, with Pracinostat tested in advanced hematologic malignancies and solid tumors. ME-344 and ME-401 address unmet needs in mitochondrial and PI3K delta pathways, respectively. MEI Pharma's revenue model relies on clinical trial progress and future commercialization of these therapies, aiming to secure partnerships or direct sales in oncology. MEI Pharma's portfolio includes three clinical drug candidates, each targeting distinct cancer mechanisms. Pracinostat is advanced in trials for AML and MDS, while ME-344 and ME-401 are in development for broader cancer applications. The company monetizes through potential drug approvals and sales, with a focus on hematologic cancers and solid tumor markets. Lite Strategy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lite Strategy stock

R&D Spending per Employee of Lite Strategy is 30,500.00 USD in 2026.

R&D Spending per Employee of Lite Strategy changed from 980,750.00 USD to 30,500.00 USD, representing a -96.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Lite Strategy since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Lite Strategy historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Lite Strategy

All Key Metrics — Lite Strategy